Search company, investor...
Flourish company logo


Founded Year



Acquired | Acquired

Total Raised


About Flourish

Flourish is a data visualization platform designed to make it easier for companies, including media organizations, to visualize and tell stories through data. The platform enables users to quickly create high-quality visualizations, stories, presentations, and other interactive content by putting their own data and text into configurable templates - removing much of the heavy-lifting (and expense) of data-driven storytelling. On February 2nd, 2022, Flourish was acquired by Canva. Terms of the transaction were not disclosed.

Headquarters Location

1 Southwark Bridge

London, England, SE1 9HL,

United Kingdom

+44 (0)20 3290 3920

Missing: Flourish's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Flourish's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Flourish

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Flourish in 1 CB Insights research brief, most recently on Aug 22, 2022.

Latest Flourish News

Quadriga Partners advised Keystone Clinical Studies on its partnership with Flourish Research, a portfolio company of NMS Capital

Nov 10, 2022

News provided by Share this article Share this article DENVER, Nov. 10, 2022 /PRNewswire/ -- Quadriga Partners, LLC ("Quadriga"), an investment bank and transaction advisory group that works closely with companies in the healthcare industry, has announced that it has advised Keystone Clinical Studies, LLC ("Keystone") in its recapitalization by, and partnership with, Flourish Research ("Flourish"), a portfolio company of NMS Capital ("NMS"). Keystone is a leading clinical research site focused on Alzheimer's Disease ("AD") and other conditions related to the Central Nervous System. The site was founded in 2003 by Dr. Cherian Verghese, who will continue to lead the organization. Terms of the transaction were not disclosed. Headquartered in Plymouth Meeting, PA, Keystone is a clinical research site focused on Alzheimer's Disease and other neurodegenerative conditions. The Company has established itself as a market leading site in recent years, gaining share in the Greater Philadelphia Area as well as a national reputation for excellence in clinical research. Keystone has been a valued source for CNS-focused clinical research and has developed deep relationships with sponsor customers, gaining strong revenue momentum in recent years. Dr. Verghese, a psychiatrist by training and a founding member of the CNS Summit, has spent more than 30 years focused on conducting clinical research and will assist with Flourish's future strategy in this therapeutic area. Dr. Verghese and the current management team will continue in their roles leading Keystone after the acquisition. Quadriga Partners advised Keystone Clinical Studies on its partnership with Flourish Research Dr. Cherian Verghese, Founder and CEO of Keystone said "Quadriga was an invaluable guide and an absolutely necessary participant through the entire transaction process. Their tireless commitment and support as well as their frank advice in the transaction was what ultimately led to its successful completion. Ethan Goodson and the Quadriga team moved very quickly to ensure we were able to explore all our options in terms of partners. Among the potential partners that we met, Flourish stood out for their vision, reputation, and operational excellence." Ethan Goodson, Managing Director at Quadriga noted "Clinical research sites and outsourced pharma services providers continue to be attractive industry sectors for investors and strategic buyers alike given the need for increased speed, quality and reliability in therapeutic research and development. We look forward to following Keystone and Flourish's ongoing success as they together continue to provide leading pharmaceutical and biotech sponsors the outsourced research services required to advance the development of critical therapeutic candidates treating AD and other diseases." Reinhold Schulz, CEO of Flourish Research, commented, "The Keystone partnership was exactly what we were looking for in terms of entering a new market in Philadelphia as well as expanding our CNS capabilities, which is one of Flourish's focus areas. I am excited to continue growing Flourish into a national market leader within the clinical research site space." Quadriga served as financial advisor and Royer Cooper Cohen Braunfeld LLC provided legal advice to Keystone. Cantor Fitzgerald & Co. served as financial advisor and McDermott Will & Emery provided legal advice to Flourish and NMS. About Quadriga Partners: Headquartered in Denver, Quadriga Partners is a premier healthcare investment bank, focused on several key sectors including outsourced pharmaceutical services, with a significant track record of success in clinical research transactions. Quadriga provides merger and acquisition advisory and growth and debt capital raising services exclusively for healthcare companies. For additional information on Quadriga, please visit For further information:

Flourish Frequently Asked Questions (FAQ)

  • When was Flourish founded?

    Flourish was founded in 2016.

  • Where is Flourish's headquarters?

    Flourish's headquarters is located at 1 Southwark Bridge, London.

  • What is Flourish's latest funding round?

    Flourish's latest funding round is Acquired.

  • How much did Flourish raise?

    Flourish raised a total of $1M.

  • Who are the investors of Flourish?

    Investors of Flourish include Canva, Founder Collective, LocalGlobe and Founders Factory.

  • Who are Flourish's competitors?

    Competitors of Flourish include Observable and 2 more.

Compare Flourish to Competitors

Tableau Software Logo
Tableau Software

Tableau Software is a provider of visual analysis and reporting solutions. Its flagship product is used by managers, business intelligence professionals, business analysts, strategic consultants, financial professionals, market researchers, scientists and engineers in nearly every industry. The company was founded in 2003 and is based in Seattle, Washington.


Qlik specializes in data discovery and user-driven business intelligence, delivering solutions ranging from reporting and self-service visual analysis to guided, embedded, and custom analytics, regardless of where data is located.

Deepnote Logo

Deepnote is building a data science notebook for teams. In the notebook, users can connect their data, explore, and analyze it. Users can easily share project links with team collaborators, or with end-users to present polished assets. All of this is done through a simple, browser-based UI that runs in the cloud.

BadVR Logo

BadVR is an immersive analytics platform that helps users see the whole picture and gain insights.

Immersion Analytics

Immersion Analytics specializes in the development of data analytics platforms by utilizing AI and machine learning algorithms. It provides evidence-based data insights to end-users. The company was founded in 2016 and is based in Natick, Massachusetts.

Kumu Logo

Kumu is a mobile playground for Filipino communities that provides live stream shows, group chats, and an alternate way to make money. The company was founded in 2018 and is based in Manila, Philippines.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.